Tear Solutions
Pharmaceuticals, 315 Old Ivy Way, Charlottesville, Virginia, 22903, United States, 1-10 Employees
Phone Number: 43********
Who is TEARSOLUTIONS
TearSolutions Inc. is a Delaware Corporation based in Charlottesville, VA. The company has successfully completed a well-powered 204 patient Phase II Proof of Concept clinical trial for t...
Read More
-
Headquarters: 315 Old Ivy Way, Charlottesville, Virginia, 22903, United States
-
Date Founded: 2013
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2833
Does something look wrong? Fix it. | View contact records from TEARSOLUTIONS
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding TearSolutions
Answer: TearSolutions's headquarters are located at 315 Old Ivy Way, Charlottesville, Virginia, 22903, United States
Answer: TearSolutions's phone number is 43********
Answer: TearSolutions's official website is https://tearsolutions.com
Answer: TearSolutions's revenue is $1 Million to $5 Million
Answer: TearSolutions's SIC: 2833
Answer: TearSolutions has 1-10 employees
Answer: TearSolutions is in Pharmaceuticals
Answer: TearSolutions contact info: Phone number: 43******** Website: https://tearsolutions.com
Answer: TearSolutions Inc. is a Delaware Corporation based in Charlottesville, VA. The company has successfully completed a well-powered 204 patient Phase II Proof of Concept clinical trial for the treatment of the signs and symptoms of dry eye in primary Sjogrens Syndrome patients. Statistically significant improvement in both sign and symptom at two weeks was found. The trial compared vehicle and two doses of LacripepTM, a novel 19 AA peptide that is present in normal tears and deficient in all forms of dry eye. The peptide restores homeostasis to the ocular surface, in particular the barrier function of the corneal epithelium and normal function of sensory nerves at the corneal surface in preclinical animal models. Restoration of epithelial barrier function can be measured clinically as a decrease in corneal fluorescein staining while the improvement in sensory nerve function restores normal production of the components of tears: the aqueous via reinnervation of lacrimal glands, the lipid via reinnervation of meibomium glands and the mucin via reinnervation of goblet cells. Improvement in fluorescein staining and tear production (Schirmer tear test) are clinical signs of dry eye that have been used in the FDA approval of Xiidra and Restasis respectively. LacripepTM was discovered at the University of Virginia with NEI funding as a naturally occurring fragment of the larger 119 AA protein, lacritin, in an unbiased screen for novel factors capable of addressing dry eye. Management team - CEO/President: Anil Asrani - Executive Chairman/Cofounder: Mark B. Logan - CSO/Cofounder: Gordon W. Laurie PhD, FARVO - CFO: Colin M. Rolph - Chief Regulatory Officer: Michelle Carpenter JD, RAC - Chief Medical Officer: Marc G. Odrich, MD - Secretary: Mac Thompson, LLD Advisory Board - Manus C. Kraff MD - Jae K. Lee PhD - J. Daniel Nelson MD, FACS, FARVO - Kazuo Tsubota MD, FARVO
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month